Results 111 to 120 of about 19,673 (227)

Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis

Journal of Clinical Apheresis, Volume 41, Issue 3, June 2026.
ABSTRACT Dual specialty ports were evaluated for safety and efficacy in therapeutic apheresis by analyzing outcomes across 97 port placement events in 88 patients, focusing on two configurations: dual Bard PowerFlow (BP2) and a combination of Bard PowerFlow with AngioDynamics SmartPort (BP + AD).
Mugtaba Swar‐Eldahab, Barnabas Obeng‐Gyasi, Paul Haste, Matthew Krosin   +3 more
wiley   +1 more source

The Risk of Cancer Associated with Immunosuppressive Therapy for Skin Diseases [PDF]

, 2006
The possible carcinogenic risk of immunosuppressive therapies is an important issue in everyday clinical practise. Carcinogenesis is a slow multi step procedure, thus a long latency period is needed before cancer develops.
Väkevä, Liisa
core  

Current evidence and applications of photodynamic therapy in dermatology [PDF]

, 2014
In photodynamic therapy (PDT) a photosensitizer – a molecule that is activated by light – is administered and exposed to a light source. This leads both to destruction of cells targeted by the particular type of photosensitizer, and immunomodulation ...
Lin, Jennifer Y, Wan, Marilyn T
core   +2 more sources

Elastolytic Granulomatous Dermatoses: Toward a Unified Clinicopathological Concept

International Journal of Dermatology, EarlyView.
Rose Kathrin Caroline Moritz, Christiane Michl, Sonja Leson   +2 more
wiley   +1 more source

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, Volume 53, Issue 5, Page 422-426, May 2026.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source

Mycosis Fungoides [PDF]

Proceedings of the Royal Society of Medicine, 1935
G B, Dowling, W, Freudenthal
openaire   +5 more sources

Thyroid Dysfunction in Mycosis Fungoides: Sonographic and Laboratory Insights

Dermatology Practical & Conceptual
Introduction: Thyroid gland affection in mycosis fungoides has been rarely reported. It occurs as extracutaneous involvement, incidentally, as a second malignancy, or as a side effect of systemic retinoids.
Dalia Halwag, Samar Mohamed Samy Gad, Eman M ElEryan, Hend Mostafa Ali Ali, Eman M Osman, Iman Mohamed Abdelmeniem   +5 more
doaj   +1 more source

CD4/CD8 double-negative mycosis fungoides: a review

Dermatology Reports
Mycosis Fungoides (MF) stands as the predominant form of primary cutaneous T-cell lymphoma (CTCL). It manifests a diverse array of clinical, histological, and immunophenotypic variations, each bearing distinct prognostic implications.
Khalid Nabil Nagshabandi, Abdulrahman Shadid, Asem Shadid, Nouf K. Almuhanna   +3 more
doaj   +1 more source

Eccrine poromatosis following chemotherapy and radiation therapy [PDF]

, 2019
Eccrine poroma presents as a single, symptomless erythematous papule in areas with a high density of eccrine sweat glands. Although rare, eccrine poromas can present as multiple lesions, otherwise known as eccrine poromatosis.
Chiu, Melvin, Kim, Gene, Nguyen, Khoa
core  

Syringotropic Mycosis Fungoides

Skin Health and Disease
Brief description of a syringotropic mycosis fungoides.
Edmond Demoulins, Clémence Berthin
openaire   +3 more sources